Content about Wart

September 14, 2011

Attacks on a human papillomavirus vaccine made amid an increasingly caustic Republican presidential primary battle have drawn a response from the manufacturer.

NEW YORK — Attacks on a human papillomavirus vaccine made amid an increasingly caustic Republican presidential primary battle have drawn a response from the manufacturer.

September 6, 2011

Armada Health Care, Hemispherx sign sales, distribution agreement for Alferon N Injection

Hemispherx Biopharma and Armada Health Care have entered a sales and marketing agreement for a drug designed to treat genital warts.

PHILADELPHIA — Hemispherx Biopharma and Armada Health Care have entered a sales and marketing agreement for a drug designed to treat genital warts.

The two companies announced Tuesday an agreement under which Hemispherx will manufacture and supply Alferon N injection (interferon alfa-n3 [human leukocyte derived]) to physicians and patients through Armada's national specialty pharmacy network. Specialty distributor BioRidge Pharma will warehouse, ship and distribute the drug, the companies said.

April 25, 2011

MinuteClinic to offer vitamin B12 injections, HPV vaccination

CVS Caremark's MinuteClinic division has expanded its suite of services to now include vitamin B12 injections and the human papillomavirus vaccination Gardasil.

WOONSOCKET, R.I. — CVS Caremark's MinuteClinic division has expanded its suite of services to now include vitamin B12 injections and the human papillomavirus vaccination Gardasil.

March 28, 2011

FDA approves topical treatment for genital warts

The Food and Drug Administration has approved a topical treatment for genital warts made by Graceway Pharmaceuticals, the drug maker said Monday.

BRISTOL, Tenn. — The Food and Drug Administration has approved a topical treatment for genital warts made by Graceway Pharmaceuticals, the drug maker said Monday.

The FDA approved Zyclara (imiquimod) cream in the 3.75% strength for patients ages 12 years and older. According to clinical trial data, the cream effectively cleared genital warts, and of patients who achieved complete clearance, only a small percentage had a recurrence 12 weeks after treatment.

February 3, 2011

Study: Gardasil is effective in preventing genital warts among males

Merck’s vaccine for human papillomavirus is 89% effective in preventing genital warts in teenage boys and young men, according to a new study.

WHITEHOUSE STATION, N.J. — Merck’s vaccine for human papillomavirus is 89% effective in preventing genital warts in teenage boys and young men, according to a new study.

The phase-3 study of Gardasil (human papillomavirus quadrivalent [types 6, 11, 16 and 18] vaccine, recombinant) in boys and men ages 16 to 26 years was published in the Feb. 3 issue of the New England Journal of Medicine. Human papillomavirus is the cause of genital and anal warts, and infection can increase the risk of developing cancer later in life.

December 23, 2010

FDA approves Merck's Gardasil for prevention of anal cancer

Merck on Wednesday announced that the Food and Drug Administration has approved Gardasil [human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant] for the prevention of anal cancer in males and females 9 to 26 years of age.

WHITEHOUSE STATION, N.J. — Merck on Wednesday announced that the Food and Drug Administration has approved Gardasil [human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant] for the prevention of anal cancer in males and females 9 to 26 years of age.

According to the company, Gardasil is the first HPV vaccine on the market available for use in both men and women, and the only one indicated to help prevent cervical, vaginal, vulvar and anal cancers and pre-cancers, as well as genital warts, caused by certain types of HPV.

November 16, 2010

FDA advisory committee recommends expanded use of Gardasil

A Food and Drug Administration advisory committee has recommended expanded approval of a vaccine for...

WHITEHOUSE STATION, N.J. — A Food and Drug Administration advisory committee has recommended expanded approval of a vaccine for genital warts.

Merck announced Wednesday that the FDA Vaccines and Related Biological Products Advisory Committee recommended approval of Gardasil (human papillomavirus quadrivalent [types 6, 11, 16 and 18] vaccine, recombinant) for males and females ages 9 to 26 years to prevent anal cancer and anal intraepithelial neoplasia, both diseases that result from infection by the human papillomavirus.

June 1, 2010

Zymaderm now available at Walgreens

Naturopathix on Wednesday announced that its homeopathic remedy Zymaderm for relief of molluscum contagiosum symptoms...

February 17, 2010

Merck: Gardasil may prevent anal warts, cancer in men

A vaccine made by Merck for preventing human papillomavirus works for preventing anal warts and...